Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer.
Current opinion in oncology（2023）
摘要
Atezolizumab or pembrolizumab have become options for adjuvant therapy in patients with completely resected NSCLC.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要